Costs and consequences: Hepatitis C seroprevalence in the military and its impact on potential screening strategies

David M. Brett‐Major, Kevin D. Frick, Jennifer A. Malia, Shilpa Hakre, Jason F. Okulicz, Charmagne G. Beckett, Linda L. Jagodinski, Michael A. Forgione, Philip L. Gould, Stephen A. Harrison, Clinton K. Murray, Francisco J. Rentas, Adam W. Armstrong, Aatif M. Hayat, Laura A. Pacha, Peter Dawson, Angelia A. Eick‐Cost, Hala H. Maktabi, Nelson L. Michael, Steven B. Cersovsky, Sheila A. Peel, Paul T. Scott – 20 October 2015 – Knowledge of the contemporary epidemiology of hepatitis C viral (HCV) infection among military personnel can inform potential Department of Defense screening policy.

Up‐regulation of histone methyltransferase SETDB1 by multiple mechanisms in hepatocellular carcinoma promotes cancer metastasis

Chun‐Ming Wong, Lai Wei, Cheuk‐Ting Law, Daniel Wai‐Hung Ho, Felice Ho‐Ching Tsang, Sandy Leung‐Kuen Au, Karen Man‐Fong Sze, Joyce Man‐Fong Lee, Carmen Chak‐Lui Wong, Irene Oi‐Lin Ng – 20 October 2015 – Epigenetic deregulation plays an important role in liver carcinogenesis. Using transcriptome sequencing, we examined the expression of 591 epigenetic regulators in hepatitis B‐associated human hepatocellular carcinoma (HCC). We found that aberrant expression of epigenetic regulators was a common event in HCC.

Intention to treat outcome of T1 hepatocellular carcinoma with the “wait and not ablate” approach until meeting T2 criteria for liver transplant listing

Neil Mehta, Monika Sarkar, Jennifer L. Dodge, Nicholas Fidelman, John P. Roberts, Francis Y. Yao – 19 October 2015 – Patients with T1 hepatocellular carcinoma (HCC; 1 lesion < 2 cm) are currently not eligible for priority listing for liver transplantation (LT). A common practice is to wait without locoregional therapy (LRT) until tumor growth occurs from T1 to T2 (1 lesion 2‐5 cm or 2‐3 lesions ≤ 3 cm) to be eligible for listing with Model for End‐Stage Liver Disease exception.

Subscribe to